Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia

Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile of these medicines.“Acute myeloid leukaemia remains a challenging blood cancer, with particularly low median survival rates in patients who cannot tolerate intensive chemotherapy given their age or underlying health,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Devel opment. “These data validate the benefit that this Venclexta/Venclyxto-based combination can bring to patients and we look forward to discussing the results with health authorities.” Data from the VIALE-A study will be shared with global health authorities and presented at an upcoming medical meeting. Venclexta has previously been granted accelerated approval by the US Food and Drug Administration (FDA) in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of people with newly-diagnosed...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Kallam A, Armitage JO Abstract INTRODUCTION: T cell lymphomas are a heterogeneous group, with varying incidences, geographic patterns, and risk factors. Although until recently approached in a manner similar to B cell lymphomas, the treatment outcomes are poor and this disease is characterized by high relapse rates. The treatment advances in PTCL have been slow compared to B cell lymphomas. The outcomes of patients who progress following stem cell transplantation are worse. AREAS COVERED: This review focuses on the novel targeted agents that are approved and/or are under investigation for patients with...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Conclusions: Results from a head-to-head study showed that, compared with secukinumab, guselkumab had lower NNTs and CPRs for PASI 75, PASI 90, and PASI 100 responses. PMID: 32479140 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Authors: Perez BA, Slover J, Edusei E, Horan A, Anoushiravani A, Kamath AF, Nelson CL Abstract BACKGROUND: Total joint arthroplasty is one of the most common surgeries performed in the United States with total knee arthroplasty (TKA) being one of the most successful surgeries for restoring function and diminishing pain. Even with the demonstrated success of TKA and a higher prevalence of arthritis and arthritis related disability among minorities, racial and gender disparity remains a constant issue in providing care for the adult reconstruction patient. AIM: To assess the role of demographics and expectations ...
Source: World Journal of Orthopaedics - Category: Orthopaedics Tags: World J Orthop Source Type: research
Publication date: Available online 1 June 2020Source: MethodsAuthor(s): Reyhaneh Manafi-Farid, Najme Karamzade-Ziarati, Reza Vali, Felix M. Mottaghy, Mohsen Beheshti
Source: Methods - Category: Molecular Biology Source Type: research
Publication date: Available online 2 June 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Dipanwita Das Mukherjee, N. Maruthi Kumar, Mukund P. Tantak, Satabdi Datta, Debabrata Ghosh Dastidar, Dalip Kumar, Gopal Chakrabarti
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - Category: Molecular Biology Source Type: research
Publication date: Available online 1 June 2020Source: Saudi Journal of Biological SciencesAuthor(s): Zhenlong Qin, Lei Wang, Guoyan Li, Xuwen Qian, Jie Zhang, Ying Guo, Guokai Liu
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
Children and adults with Philadelphia chromosome–like B cell acute lymphoblastic leukemia (Ph-like B-ALL) experience high relapse rates despite best-available conventional chemotherapy. Ph-like ALL is driven by genetic alterations that activate constitutive cytokine receptor and kinase signaling, and early-phase trials are investigating the potential of the addition of tyrosine kinase inhibitors (TKIs) to chemotherapy to improve clinical outcomes. However, preclinical studies have shown that JAK or PI3K pathway inhibition is insufficient to eradicate the most common cytokine receptor–like factor 2–rearran...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Th17 cells (producing IL-17) and Th9 cells (producing IL-9) exhibit functional plasticity, and their role in tumorigenicity is controversial. Th17/IL-17 and Th9/IL-9 exhibit critical, but often opposing, roles in tumor progression. In this issue of the JCI, Salazar et al. show that while IL-17 and IL-9 induced distinct but complementary molecular pathways, both cytokines also induced epithelial-mesenchymal transition (EMT) in lung cancer cells and promoted metastatic spreading. A key question before us now is whether IL-9 and IL-17 contribute to tumor progression in a sequential and stage-specific manner within the tumor microenvironment.
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Emerging immune therapy, such as with the anti–programmed cell death–1 (anti–PD-1) monoclonal antibody nivolumab, has shown efficacy in tumor suppression. Patients with terminal cancer suffer from cancer pain as a result of bone metastasis and bone destruction, but how PD-1 blockade affects bone cancer pain remains unknown. Here, we report that mice lacking Pdcd1 (Pd1−/−) demonstrated remarkable protection against bone destruction induced by femoral inoculation of Lewis lung cancer cells. Compared with WT mice, Pd1−/− mice exhibited increased baseline pain sensitivity, but the deve...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Allergy & Immunology | Biotechnology | Cancer | Cancer & Oncology | Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Diabetes | Endocrinology | Food and Drug Administration (FDA) | Infectious Diseases | International Medicine & Public Health | Internet | Japan Health | Leukemia | Lung Cancer | Lymphoma | Men | Opthalmology | Pharmaceuticals | Primary CNS Lymphoma | Rituxan | Science | Statistics | Study | Switzerland Health | USA Health | WHO